-
1Academic Journal
Source: Высшая школа: научные исследования.
Subject Terms: ДГПЖ, хирургическое лечение, Доброкачественная гиперплазия предстательной железы, трансуретральная резекция предстательной железы, ТУР ПЖ
-
2Academic Journal
Contributors: The authors declare no funding, Авторы заявляют об отсутствии финансовой поддержки
Source: Obstetrics, Gynecology and Reproduction; Vol 19, No 5 (2025); 776-787 ; Акушерство, Гинекология и Репродукция; Vol 19, No 5 (2025); 776-787 ; 2500-3194 ; 2313-7347
Subject Terms: мужчины, benign prostatic hyperplasia, BPH, testosterone, estradiol, men, доброкачественная гиперплазия предстательной железы, ДГПЖ, тестостерон, эстрадиол
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/2529/1399; Cannarella R., Condorelli R.A., Barbagallo F. et al. Endocrinology of the aging prostate: current concepts. Front Endocrinol (Laussane). 2021;12:554078. https://doi.org/10.3389/fendo.2021.554078.; Vuichoud C., Loughlin K.R. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22(Suppl 1):1–6.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332.; De Santis C.E., Siegel R.L., Sauer A.G. et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66(4):290–308. https://doi.org/10.3322/caac.21340.; Rohrmann S., Nelson W.G., Rifai N. et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab. 2007;92(7):2519–25. https://doi.org/10.1210/jc.2007-0028.; Williams V.L., Awasthi S., Fink A.K. et al. African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015. Cancer Med. 2018;7(5):2160–71. https://doi.org/10.1002/cam4.1451.; Каприн А.Д., Алексеев Б.Я., Матвеев В.Б. и др. Рак предстательной железы. Клинические рекомендации. Современная oнкология. 2021;23(2):211–47. https://doi.org/10.26442/18151434.2021.2.200959.; Rider J.R., Wilson K.W., Sinnott J.A. et al. Ejaculation frequency and risk of prostate cancer: updated results with an additional decade of follow-up. Eur Urol. 2016;70(6):974–82. https://doi.org/10.1016/j.eururo.2016.03.027.; Pernar C.H., Ebot E.M., Wilson K.M., Mucci L.A. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8(12):a030361. https://doi.org/10.1101/cshperspect.a030361.; Дедов И.И., Мельниченко Г.А., Фадеев В.Ф. Руководство по эндокринологии. M.: ГЭОТАР-Медиа, 2007. 432 с.; Зильбер А.П. Синдромы сонного апноэ: клиническая физиология, лечение, профилактика. Петрозаводск: Изд-во Петрозаводского университета, 1994. 184 с.; Al-Shboul O.A., Mustafa A.G., Omar A.A. et al. Effect of progesterone on nitric oxide/cyclic guanosine monophosphate signaling and contraction in gastric smooth muscle cells. Biomed Rep. 2018;9(6):511–6. https://doi.org/10.3892/br.2019.1251.; Alqudah M., Al-Shboul O., Al Dwairi A. et al. Progesterone inhibitory role on gastrointestinal motility. Physiol Res. 2022;71(2):193–8. https://doi.org/10.33549/physiolres.934824.; Shackleton C., Malunowicz E. Apparent pregnene hydroxylation deficiency (APDH): seekingthe parentage of an orphan metabolome. Steroids. 2003;68(9):707–17. https://doi.org/10.1016/s0039-128x(03)00115-6.; Oettel M., Mukhopadhyay A.K. Progesterone: the forgotten hormone in man. Aging Male. 2004;7(3):236–57. https://doi.org/10.1080/13685530400004199.; Федотчева Т.А. Клиническое применение прогестинов и механизмы их действия: настоящее и будущее (обзор). Современные технологии в медицине. 2021;13(1):93–108. https://doi.org/10.17691/stm2021.13.1.11.; Graham J.D., Clarcke C.L. Physiological action of progesterone in target tissues. Endocr Rev. 1997;18(4):502–19. https://doi.org/10.1210/edrv.18.4.0308.; Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8 Suppl 1:3–63. https://doi.org/10.1080/13697130500148875.; Якушевская О.В. Современные подходы к назначению прогестерона в практике акушера-гинеколога. Эффективная фармакотерапия. Акушерство и гинекология. 2012;(4):12–6.; Baranizadeh K., Mahboobian M.M., Amiri I. et al. Effects of progesterone nanoparticles on the sperm capacitation and acrosome reaction in asthenozoospermia men. Andrologia. 2022;54(1):e14258. https://doi.org/10.1111/and.14258.; Sutter-Dub M. Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types. Steroids. 2002;67(2):77–93. https://doi.org/10.1016/s0039-128x(01)00142-8.; Ghandehari S., Matusov Y., Pepkowitz S. et al. Progesterone in addition to standard of care vs standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19: a randomized, controlled pilot trial. Chest. 2021;160(1):74–84. https://doi.org/10.1016/j.chest.2021.02.024.; Beltrame A., Salguero P., Rossi E. et al. Immunometabolic mechanisms underlying the severity of COVID-19. Viral Immunol. 2022;13:1–10. https://doi.org/10.3389/fimmu.2022.834851.; Mauvais-Jarvis F., Klein S.L., Levin E.R. Estradiol, progesterone, immunomodulation, and COVID-19 outcomes. Endocrinology. 2020;161(9):bqaa127. https://doi.org/10.1210/endocr/bqaa127.; Physicians desk reference. Montvale N.J.: Thomson P.D.R., 2006. 60th ed. 3529 p.; Garg D., Ng S.S.M., Baig K.M. et al. Progesterone-mediated non-classical signaling. Trends Endocrinol Metab. 2017;28(9):656–68. https://doi.org/10.1016/j.tem.2017.05.006.; Wetendorf M., DeMayo F.J. Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus. Int J Dev Biol. 2014;58(2–4):95–106. https://doi.org/10.1387/ijdb.140069mw.; Valadez-Cosmes P., Vázquez-Martínez E.R., Cerbon M., Camacho-Arroyo I. Membrane progesterone receptors in reproduction and cancer. Mol Cell Endocrinol. 2016;434:166–75. https://doi.org/10.1016/j.mce.2016.06.027.; Kolatorova L., Vitku J., Suchopar J. et al. Progesterone: a steroid with wide range of effects in physiology as well as human medicine. Int J Mol Sci. 2022;23(14):7989. https://doi.org/10.3390/ijms23147989.; Haseroth K., Christ M., Falkenstein E., Wehling M. Aldosterone- and progesterone-membrane-binding proteins: new concepts of nongenomic steroid action. Curr Protein Pept Sci. 2000;1(4):385–401. https://doi.org/10.2174/1389203003381270.; Falkenstein E., Heck M., Gerdes D. et al. Specific progesterone binding to a membrane protein and related nongenomic effects on Ca2+-fluxes in sperm. Endocrinology. 1999;140(12):5999–6002. https://doi.org/10.1210/endo.140.12.7304.; Falkenstein E., Tillmann H.C., Christ M. et al. Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol Rev. 2000;52(4):513–56. https://doi.org/10.1016/S0031-6997(24)01468-6.; Simoncini T., Genazzani A.R. Non-genomic actions of sex steroid hormones. Eur J Endocrinol. 2003;148(3):281–92. https://doi.org/10.1530/eje.0.1480281.; Conneely O.M., Lydon J.P. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids. 2000;65(10–11):571–7. https://doi.org/10.1016/s0039-128x(00)00115-x.; Cassidenti D.L., Paulson R.J., Serafini P. et al. Effects of sex steroids on skin 5 alpha-reductase activity in vitro. Obstet Gynecol. 1991;78(1):103–7.; Hou Z., Huang S., Mei Z. et al. Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer. Cell Rep Med. 2022;3(3):100561. https://doi.org/10.1016/j.xcrm.2022.100561.; Chen G., Shi J.-X., Qi M. et al. Effects of progesterone on intestinal inflammatory response, mucosa structure alterations, and apoptosis following traumatic brain injury in male rats. J Surg Res. 2008;147(1):92–8. https://doi.org/10.1016/j.jss.2007.05.029.; Nalli A.D., Kumar D.P., Mahavadi S. et al. Hypercontractility of intestinal longitudinal smooth muscle induced by cytokines is mediated by the nuclear factor-κB/AMP-activated kinase/myosin light chain kinase pathway. J Pharmacol Exp Therap. 2014;350(1):89–98. https://doi.org/10.1124/jpet.113.212522.; Pang Y., Dong J., Thomas P. Progesterone increases nitric oxide synthesis in human vascular endothelial cells through activation of membrane progesterone receptor-α. Am J Physiol Endocrinol Metab. 2015;308(10):E899–E911. https://doi.org/10.1152/ajpendo.00527.2014.; Andriole G.L., Humphrey P., Ray P. et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol. 2004;172(3):915–9. https://doi.org/10.1097/01.ju.0000136430.37245.b9.; Clark R.V., Hermann D.J., Cunningham G.R. et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179–84. https://doi.org/10.1210/jc.2003-030330.; McConnell J.D., Wilson J.D., George F.W. et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74(3):505–8. https://doi.org/10.1210/jcem.74.3.1371291.; Span P.N., Voller M.C., Smals A.G. et al Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol. 1999;161(1):332–7.; Wu Y., Godoy A., Azzouni F. et al. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors. Prostate. 2013;73(13):1470–82. https://doi.org/10.1002/pros.22694.; Lazier C.B., Thomas L.N., Douglas R.C. et al. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate. 2004;58(2):130–44. https://doi.org/10.1002/pros.10340.; Wu Y., Chhipa R.R., Zhang H., Ip C. The antiandrogenic effect of finasteride against a mutant androgen receptor. Cancer Biol Ther. 2011;11(10):902–9. https://doi.org/10.4161/cbt.11.10.15187.; https://www.gynecology.su/jour/article/view/2529
-
3Academic Journal
Authors: M. I. Kogan, M. E. Efremov, V. L. Medvedev, T. G. Sinyavskaya, М. И. Коган, М. Е. Ефремов, В. Л. Медведев, Т. Г. Синявская
Source: Urology Herald; Том 13, № 1 (2025); 13-18 ; Вестник урологии; Том 13, № 1 (2025); 13-18 ; 2308-6424 ; 10.21886/2308-6424-2025-13-1
Subject Terms: диагностика, benign prostate hyperplasia, diagnosis, гиперплазия предстательной железы
File Description: application/pdf
Relation: https://www.urovest.ru/jour/article/view/1005/618; Пушкарь Д.Ю., Раснер П.И. Дифференциальная диагностика рака и доброкачественной гиперплазии предстательной железы. РМЖ. 2014;17:1298. eLIBRARY ID: 21846217; EDN: SKBOXD; Рак предстательной железы: протеомика, геномика, хирургия. Под ред. Коган М.И., Пушкарь Д.Ю. М.: АБВ-пресс; 2019. ISBN: 978 5 903018 64 2; Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, Hamilton W. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20(1):54. DOI:10.1186/s12916-021-02230-y; Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019;4(4):CD012663. DOI:10.1002/14651858.CD012663.pub2; Wagaskar VG, Levy M, Ratnani P, Moody K, Garcia M, Pedraza AM, Parekh S, Pandav K, Shukla B, Prasad S, Sobotka S, Haines K, Punnen S, Wiklund P, Tewari A. Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer. Eur Urol Open Sci. 2021;28:9-16. DOI:10.1016/j.euros.2021.03.008; Коган М.И., Киреев А.Ю. Анкета интегральной оценки мужской сексуальности. Урология. 2009;(1):46-50. eLIBRARY ID: 12162910; EDN: KGEESH; Farrell C, Noyes SL, Joslin J, Varma M, Moriarity A, Buchach C, Mammen L, Lane BR. Prostate Multiparametric Magnetic Resonance Imaging Program Implementation and Impact: Initial Clinical Experience in a Community Based Health System. Urol Pract. 2018;5(3):165-171. DOI:10.1016/j.urpr.2017.03.009; Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A metaanalysis. Ann Oncol. 2015;26(5):848-864. DOI:10.1093/annonc/mdu525; Roobol MJ, Verbeek JFM, van der Kwast T, Kümmerlin IP, Kweldam CF, van Leenders GJLH. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. Eur Urol. 2017;72(1):45-51. DOI:10.1016/j.eururo.2017.01.033; Schoots IG, Roobol MJ. Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions. World J Urol. 2020;38(3):517-529. DOI:10.1007/s00345-019-02707-9; Saba K, Wettstein MS, Lieger L, Hötker AM, Donati OF, Moch H, Ankerst DP, Poyet C, Sulser T, Eberli D, Mortezavi A. External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer. J Urol. 2020;203(4):719-726. DOI:10.1097/JU.0000000000000622; Peters M, Eldred-Evans D, Kurver P, Falagario UG, Connor MJ, Shah TT, Verhoeff JJC, Taimen P, Aronen HJ, Knaapila J, Montoya Perez I, Ettala O, Stabile A, Gandaglia G, Fossati N, Martini A, Cucchiara V, Briganti A, Lantz A, Picker W, Haug ES, Nordström T, Tanaka MB, Reddy D, Bass E, van Rossum PSN, Wong K, Tam H, Winkler M, Gordon S, Qazi H, Boström PJ, Jambor I, Ahmed HU. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score. Eur Urol. 2022;82(5):559-568. DOI:10.1016/j.eururo.2022.07.022; Коган М.И., Ефремов М.Е., Медведев В.Л., Аносов А.Д., Братова А.В. Половая конституция (сексуальность) мужчин с раком предстательной железы. Урология. 2024;(6):56-60. DOI: https://dx.doi.org/10.18565/urology.2024.6.53-60; https://www.urovest.ru/jour/article/view/1005
-
4Academic Journal
Subject Terms: пептидно-цитокиновый комплекс «Суперлимф 25 ЕД», benign prostatic hyperplasia, prostatitis, пациенты, peptide-cytokine complex 'Superlymph 25 U', иммуномодулятор, immunomodulator, доброкачественная гиперплазия предстательной железы, простатит, patients, older age group, старшая возрастная группа
-
5Academic Journal
Authors: Kussainov, A.M., Salmenbaeva, A.B., Musulmanbek, M.E., Bulegenov, T.A., Omarov, N.B., Akimzhanov, K.D., Kuderbayev, M.Т., Kolyado, V.B.
Source: Наука и здравоохранение. :127-132
Subject Terms: benign prostatic hyperplasia, өлім-жітім, смертность, эпидемиология, epidemiology, доброкачественная гиперплазия предстательной железы, Қазақстан, Казахстан, mortality, қуық асты безінің қатерсіз гиперплазиясы, Kazakhstan, 3. Good health
-
6Academic Journal
Authors: Kussainov, A.M., Shalgumbayeva, G.M., Bulegenov, T.A., Salmenbaeva, A.B., Musulmanbek, M.E.
Source: Наука и здравоохранение. :121-27
Subject Terms: хирургиялық емдеу, surgical treatment, Benign prostatic hyperplasia (BPH), outcome, исход, оперативное лечение, нәтиже, Қазақстан, Казахстан, Қуықасты безінің қатерсіз гиперплазиясы (ҚБҚГ), Kazakhstan, 3. Good health, Доброкачественная гиперплазия предстательной железы (ДГПЖ)
-
7Academic Journal
Authors: Kairambayev, Ye.М., Bulegenov, T.А., Akimzhanov, K.D., Kuderbayev, M.Т., Neimark, A.I., Smail, Ye.M., Yurkovskaya, O.A., Zhumanbayeva, Zh.М., Glushkova, N.E.
Source: Наука и здравоохранение. :105-110
Subject Terms: surgery, benign prostatic hyperplasia, эректильная функция, эректильді функция, оперативное вмешательство, 5-фторурацил, 5-fluorouracil, erectile function, доброкачественная гиперплазия предстательной железы, хирургия, қуық асты безінің қатерсіз гиперплазиясы, 3. Good health
-
8Conference
Subject Terms: ЛИКОПИН, ДОБРОКАЧЕСТВЕННАЯ ГИПЕРПЛАЗИЯ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, МОЛОЧНЫЙ ЙОДИРОВАННЫЙ БЕЛОК
File Description: application/pdf
Access URL: http://elar.urfu.ru/handle/10995/135201
-
9Academic Journal
Authors: Kairambayev, Ye.М., Bulegenov, T.A., Kuderbayev, M.T., Zhussupov, S.M., Messova, A.M., Yurkovskaya, O.А., Yurkovsky, A.
Source: Наука и здравоохранение. :188-198
Subject Terms: benign prostatic hyperplasia, стриктуры уретры, емі, treatment, risk factors, факторы риска, доброкачественная гиперплазия предстательной железы, лечение, urethral strictures, Қуық асты безінін катерсіз гиперплазиясы, уретра стриктурасы, кауіп қатер факторы, 3. Good health
-
10Academic Journal
Authors: S. V. Kotov, R. A. Perov, I. A. Zhestkov, A. A. Novikov, A. A. Nemenov, С. В. Котов, Р. А. Перов, И. А. Жестков, А. А. Новиков, А. А. Неменов
Source: Urology Herald; Том 12, № 2 (2024); 33-42 ; Вестник урологии; Том 12, № 2 (2024); 33-42 ; 2308-6424 ; 10.21886/2308-6424-2024-12-2
Subject Terms: хирургическое лечение гиперплазии простаты, benign prostate hyperplasia, laser enucleation, surgery, гиперплазия предстательной железы, лазерная энуклеация простаты
File Description: application/pdf
Relation: https://www.urovest.ru/jour/article/view/853/548; Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474-9. DOI:10.1016/s0022-5347(17)49698-4; Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49. DOI:10.1016/s0090-4295(02)02243-4; Kupelian V, Wei JT, O'Leary MP, Kusek JW, Litman HJ, Link CL, McKinlay JB; BACH Survery Investigators. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006;166(21):2381-7. DOI:10.1001/archinte.166.21.2381; Cornu JN, Gacci M, Hashim H, Herrmann TRW, Malde S, Netsch C, Rieken M, Sakalis V, Tutolo M. EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology; 2023.; Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, Gandhi MC, Kaplan SA, Kohler TS, Martin L, Parsons JK, Roehrborn CG, Stoffel JT, Welliver C, Wilt TJ. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Workup and Medical Management. J Urol. 2021;206(4):806-817. Erratum in: J Urol. 2021;206(5):1339. DOI:10.1097/JU.0000000000002183; Пешехонов К.С., Шпиленя Е.С., Комяков Б.К., Бурлака О.О., Саргсян М.С. Сравнительный анализ резекционной и энуклеационных методик эндоскопического лечения гиперплазии предстательной железы у пациентов пожилого возраста. Вестник урологии. 2020;8(1):25-38. DOI:10.21886/2308-6424-2020-8-1-25-38; Еникеев Д.В., Глыбочко П.В., Аляев Ю.Г., Рапопорт Л.М., Сорокин Н.И., Суханов Р.Б., Спивак Л.Т., Хамраев О.Х., Тараткин М.С., Лаухтина Е.А. Сравнительный анализ эффективности различных методик эндоскопической энуклеации простаты. Хирургия. Журнал им. Н.И. Пирогова. 2017;(11):4-14. DOI:10.17116/hirurgia2017114-14; Zhong J, Feng Z, Peng Y, Liang H. A Systematic Review and Meta-analysis of Efficacy and Safety Following Holmium Laser Enucleation of Prostate and Transurethral Resection of Prostate for Benign Prostatic Hyperplasia. Urology. 2019;131:14-20. DOI:10.1016/j.urology.2019.03.034; Хубларов О.Ю. Гольмиевая лазерная энуклеация простаты, особенности выполнения вмешательства. Вестник урологии. 2014;(2):25-40. DOI:10.21886/2308-6424-2014-0-2-25-40; Котов С.В., Суренков Д.Н., Акритиди А.А., Барабаш М.И., Семенов Р.А., Бугаенко О.А., Джохадзе Л.С. Гольмиевая лазерная энуклеация предстательной железы – новый «золотой стандарт» хирургического лечения ДГПЖ в г. Москве. Экспериментальная и клиническая урология. 2020;13(5):64-70. DOI:10.29188/2222-8543-2020-13-5-64-70; Wroclawski ML, Teles SB, Amaral BS, Kayano PP, Cha JD, Carneiro A, Alfer W Jr, Monteiro J Jr, Gil AO, Lemos GC. A systematic review and meta-analysis of the safety and efficacy of endoscopic enucleation and non-enucleation procedures for benign prostatic enlargement. World J Urol. 2020;38(7):1663-1684. DOI:10.1007/s00345-019-02968-4; Kuntz RM, Lehrich K, Ahyai S. Does perioperative outcome of transurethral holmium laser enucleation of the prostate depend on prostate size? J Endourol. 2004;18(2):183-8. DOI:10.1089/089277904322959842; Glybochko PV, Rapoport LM, Enikeev ME, Enikeev DV. Holmium laser enucleation of the prostate (HoLEP) for small, large and giant prostatic hyperplasia: tips and tricks. Urologia. 2017;84(3):169-173. DOI:10.5301/uj.5000232; Zell MA, Abdul-Muhsin H, Navaratnam A, Cumsky J, Girardo M, Cornella J, Nevo A, Cheney S, Humphreys MR. Holmium laser enucleation of the prostate for very large benign prostatic hyperplasia (≥ 200 cc). World J Urol. 2021;39(1):129-134. DOI:10.1007/s00345-020-03156-5; Placer J, Gelabert-Mas A, Vallmanya F, Manresa JM, Menéndez V, Cortadellas R, Arango O. Holmium laser enucleation of prostate: outcome and complications of self-taught learning curve. Urology. 2009;73(5):1042-8. DOI:10.1016/j.urology.2008.12.052; Krambeck AE, Handa SE, Lingeman JE. Holmium laser enucleation of the prostate for prostates larger than 175 grams. J Endourol. 2010;24(3):433-7. DOI:10.1089/end.2009.0147; El-Hakim A, Elhilali MM. Holmium laser enucleation of the prostate can be taught: the first learning experience. BJU Int. 2002;90(9):863-9. DOI:10.1046/j.1464-410x.2002.03071.x; https://www.urovest.ru/jour/article/view/853
-
11Academic Journal
Authors: M. I. Katibov, A. B. Bogdanov, M. M. Alibekov, Z. M. Magomedov, O. B. Loran, М. И. Катибов, А. Б. Богданов, М. М. Алибеков, З. М. Магомедов, О. Б. Лоран
Source: Urology Herald; Том 12, № 1 (2024); 27-35 ; Вестник урологии; Том 12, № 1 (2024); 27-35 ; 2308-6424 ; 10.21886/2308-6424-2024-12-1
Subject Terms: тулиевый лазер, benign prostatic hyperplasia, transurethral resection, laser enucleation, thulium laser, доброкачественная гиперплазия предстательной железы, трансуретральная резекция, лазерная энуклеация
File Description: application/pdf
Relation: https://www.urovest.ru/jour/article/view/827/531; Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36(4):403-415, v. DOI:10.1016/j.ucl.2009.07.003; Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology. 2012;79(5):1111-1116. DOI:10.1016/j.urology.2011.11.084; Naspro R, Bachmann A, Gilling P, Kuntz R, Madersbacher S, Montorsi F, Reich O, Stief C, Vavassori I. A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol. 2009;55(6):1345-1357. DOI:10.1016/j.eururo.2009.03.070; Patel A, Nunez R, Mmeje CO, Humphreys MR. Safety and feasibility of concomitant surgery during holmium laser enucleation of the prostate (HoLEP). World J Urol. 2014;32(6):1543-1549. DOI:10.1007/s00345-014-1254-0; Myers JB, McAninch JW. Perineal urethrostomy. BJU Int. 2011;107(5):856-865. DOI:10.1111/j.1464-410X.2011.10139.x; Bracka A. A versatile two-stage hypospadias repair. Br J Plast Surg. 1995;48(6):345-352. DOI:10.1016/s0007-1226(95)90023-3; Chong T, Li YQ, Wang ZM, Shi T, Zhang P. [Simultaneous treatment for benign prostate hyperplasia and its concomitant diseases]. Zhonghua Nan Ke Xue. 2006;12(6):534-536. (In Chinese) PMID: 16833196; Коган М.И., Митусов В.В., Красулин В.В., Шангичев А.В., Глухов В.П., Аметов Р.Э., Митусова Е.В. Внутренняя оптическая уретротомия при стриктурной болезни уретры усложняет последующую реконструктивную операцию. Урология. 2012;(3):27-30. eLIBRARY ID: 18065089; EDN: PFIHBD; Коган М.И. Комментарии к новым поправкам (2023) в рекомендации Американской урологической ассоциации по стриктурной болезни уретры. Вестник урологии. 2023;11(3):5-9. DOI:10.21886/2308-6424-2023-11-3-5-9; Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral Stricture Disease Guideline Amendment (2023). J Urol.2023;210(1):64-71. DOI:10.1097/JU.0000000000003482; Катибов М.И., Богданов А.Б. Перинеальная уретростомия: результаты, клинико-статистические и терминологические аспекты. Урология. 2022;(2):113-120. DOI:10.18565/urology.2022.2.113-120; Глухов В.П., Ильяш А.В., Митусов В.В., Сизякин Д.В., Коган М.И. Роль перинеальной уретростомии в лечении пациентов со стриктурами спонгиозной уретры. Вестник урологии. 2022;10(2):87-98. DOI:10.21886/2308-6424-2022-10-2-87-98; Verla W, Oosterlinck W, Waterloos M, Spinoit AF, Lumen N. Perineal Urethrostomy for Complicated Anterior Urethral Strictures: Indications and Patient's Choice. An Analysis at a Single Institution. Urology. 2020;138:160-165. DOI:10.1016/j.urology.2019.11.064; Arya MC, Singhal A, Vasudeo V, Shyoran Y, Gandhi A, Maan R, Sonwal M. Perineal urethrostomy: A single-stage viable option for complex anterior urethral strictures. Urol Ann. 2021;13(2):142-149. DOI:10.4103/UA.UA_111_20; Yadav P, Danish N, Sureka SS, Rustagi S, Kapoor R, Srivastava A, Singh UP. Permanent perineal urethrostomy for anterior urethral strictures: A critical appraisal of long-term outcomes and erectile function. Turk J Urol. 2021;47(2):158-163. DOI:10.5152/tud.2020.20322; Abedi A, Razzaghi MR, Rahavian A, Hazrati E, Aliakbari F, Vahedisoraki V, Allameh F. Is Holmium Laser Enucleation of the Prostate a Good Surgical Alternative in Benign Prostatic Hyperplasia Management? A Review Article. J Lasers Med Sci. 2020;11(2):197-203. DOI:10.34172/jlms.2020.33; Yilmaz M, Esser J, Suarez-Ibarrola R, Gratzke C, Miernik A. Safety and Efficacy of Laser Enucleation of the Prostate in Elderly Patients – A Narrative Review. Clin Interv Aging. 2022;17:15-33. DOI:10.2147/CIA.S347698; Hartung FO, Kowalewski KF, von Hardenberg J, Worst TS, Kriegmair MC, Nuhn P, Herrmann TRW, Michel MS, Herrmann J. Holmium Versus Thulium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus. 2022;8(2):545-554. DOI:10.1016/j.euf.2021.03.024; https://www.urovest.ru/jour/article/view/827
-
12Academic Journal
Authors: V. Yu. Startsev, V. A. Dudarev, В. Ю. Старцев, В. А. Дударев
Source: Urology Herald; Том 12, № 5 (2024); 33-44 ; Вестник урологии; Том 12, № 5 (2024); 33-44 ; 2308-6424 ; 10.21886/2308-6424-2024-12-5
Subject Terms: биомаркеры, benign prostatic hyperplasia, biomarkers, гиперплазия предстательной железы
File Description: application/pdf
Relation: https://www.urovest.ru/jour/article/view/956/596; Земскова С, Шабунина В, Гертнер Л, Мухин В, Ильина Е, Корякин А. Влияние консервативного и оперативного лечения заболеваний мочеполовых органов на иммунологическую реактивность пациентов. Вестник экспериментальной и клинической хирургии. 2010;3(4):408-414.; Vasconcelos CTM, Gomes MLS, Geoffrion R, Saboia DM, Bezerra KC, Vasconcelos Neto JA.Pessary evaluation for genital prolapse treatment: From acceptance to successful fitting. Neurourol Urodyn. 2020;39(8):2344-2352. DOI:10.1002/nau.24493; Аполихин О.И., Комарова В.А., Никушина А.А., Сивков А.В. Болезни предстательной железы в Российской Федерации: статистические данные 2008-2017 гг. Экспериментальная и клиническая урология. 2019;2:4-13. DOI:10.29188/2222-8543-2019-11-2-4-12; Коротеев М.А., Кореньков Д.Г., Михайличенко В.В. Ранняя профилактика инфекционно-воспалительных осложнений трансуретральной резекции доброкачественной гиперплазии предстательной железы. Андрология и генитальная хирургия. 2008(2):55-61.; Wong A, Mahmalji W. The role of Rezūm ™ team ablation of the prostate in the treatment of patients with acute urinary retention secondary to benign prostatic hyperplasia. A single center, single surgeon case series and literature review. Aging Male. 2020;23(5):1620-1626. DOI:10.1080/13685538.2021.1901273; Дударев В.А., Кошмелев А.А., Старцев В.Ю. Частота и причины осложнений гиперплазии предстательной железы, по данным исследования жителей региона России (Забайкальский край). Забайкальский медицинский вестник. 2017;2:161-169. eLIBRARY ID: 29409312; EDN: YTOQZV; Старцев В.Ю., Дударев В.А., Кошмелев А.А. Причины осложнений гиперплазии предстательной железы у жителей региона России. Урологические ведомости. 2017;7(S):101-102. eLIBRARY ID: 29246515; EDN: YQAATP; Swavely NR, Speich JE, Stothers L, Klausner AP. New Diagnostics for Male Lower Urinary Tract Symptoms. Curr Bladder Dysfunct Rep. 2019;14:90-97. DOI:10.1007/s11884-019-00511-0; Cho KJ, Koh JS, Choi J, Kim JC. Changes in Adenosine Triphosphate and Nitric Oxide in the Urothelium of Patients with Benign Prostatic Hyperplasia and Detrusor Underactivity. J Urol. 2017;198(6):1392-1396. DOI:10.1016/j.juro.2017.06.080; Дударев В.А., Старцев В.Ю. Факторы прогноза развития нарушений мочеиспускания при гиперплазии предстательной железы у мужчин пожилого возраста. Урология. 2018;(6):150-154. DOI:10.18565/urology.2018.6.150-154; Gharaee-Kermani M, Macoska JA. Promising molecular targets and biomarkers for male BPH and LUTS. Curr Urol Rep. 2013;14(6):628-637. DOI:10.1007/s11934-013-0368-z; Young S, Gasparetto A, Jalaeian H, Golzarian J. Biomarkers in the setting of benign prostatic hyperplasia-induced lower urinary tract symptoms: what an interventional radiologist needs to know. Br J Radiol. 2020;93(1114):20200484. DOI:10.1259/bjr.20200484; Ma J, Gharaee-Kermani M, Kunju L, Hollingsworth JM, Adler J, Arruda EM, Macoska JA. Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol. 2012;188(4):1375-1381. DOI:10.1016/j.juro.2012.06.007; Rodriguez-Nieves JA, Macoska JA. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol. 2013;10(9):546-550. DOI:10.1038/nrurol.2013.149; Gheinani AH, Kiss B, Moltzahn F, Keller I, Bruggmann R, Rehrauer H, Fournier CA, Burkhard FC, Monastyrskaya K. Characterization of miRNA-regulated networks, hubs of signaling, and biomarkers in obstruction-induced bladder dysfunction. JCI Insight. 2017;2(2):e89560. DOI:10.1172/jci.insight.89560; Ахохов З.М., Исмаилов Р.С., Коган М.И. Роль микроРНК в качестве молекулярно-биологических маркёров дифференциации доброкачественной гиперплазии и рака предстательной железы. Вестник урологии. 2023;11(3):98-107. DOI:10.21886/2308-6424-2023-11-3-98-107; Кирпатовский В.И., Мудрая И.С., Федяков Р.П., Голованов С.А., Дрожжева В.В., Черников Д.Ю., Елисеев Д.Э., Надточий О.Н., Сыромятникова Е.В. Ферментурия как маркер повреждения мочевого пузыря при острой задержке мочи. Экспериментальная и клиническая урология. 2012;1:20-23. eLIBRARY ID: 17775523; EDN: OYZNNP; Кобалава Ж.Д., Виллевальде С.В., Ефремовцева М.А., Моисеев В.С. Биомаркеры острого повреждения почек: современные представления и перспективы. Терапевтический архив. 2014;86(6):88-93. eLIBRARY ID: 22372998; EDN: SVPHNF; Кирпатовский В.И, Орлова Е.В., Харламова Л.А., Голованов С.А., Дрожжева В.В., Фролова Е.В. Значимость динамического определения концентрации цистатина С в крови как маркера риска перехода острого повреждения почек в хроническую почечную недостаточность и эффективности нефропротективной терапии. Экспериментальная и клиническая урология. 2021;14(4):20-29. DOI:10.29188/2222-8543-2021-14-4-20-29; Mello MF, de Bessa J Júnior, Reis ST, Kondo EY, Yu L, Dénes FT, Lopes RI. Evaluating TIMP-2 and IGFBP-7 as a predictive tool for kidney injury in ureteropelvic junction obstruction. Int Braz J Urol. 2022;48(2):284-293. DOI:10.1590/S1677-5538.IBJU.2021.0340; Nalesso F, Cattarin L, Gobbi L, Fragasso A, Garzotto F, Calò LA. Evaluating Nephrocheck® as a Predictive Tool for Acute Kidney Injury. Int J Nephrol Renovasc Dis. 2020;13:85-96. DOI:10.2147/IJNRD.S198222; Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl. 2008;241:89-94. DOI:10.1080/00365510802150158; Прокопьева Н. Э., Новикова В.П. Современные биомаркеры повреждения почек. Медицина: теория и практика. 2018;3(3 приложен):29-35. eLIBRARY ID: 36546415; EDN: YPURYT; Astor BC, Köttgen A, Hwang SJ, Bhavsar N, Fox CS, Coresh J. Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study. Am J Nephrol. 2011;34(4):291-297. DOI:10.1159/000330699; Tanaka K, Sugiyama H, Yamanari T, Mise K, Morinaga H, Kitagawa M, Onishi A, Ogawa-Akiyama A, Tanabe K, Eguchi J, Ohmoto Y, Shikata K, Wada J. Renal expression of trefoil factor 3 mRNA in association with tubulointerstitial fibrosis in IgA nephropathy. Nephrology (Carlton). 2018;23(9):855-862. DOI:10.1111/nep.13444; Rinnert M, Hinz M, Buhtz P, Reiher F, Lessel W, Hoffmann W. Synthesis and localization of trefoil factor family (TFF) peptides in the human urinary tract and TFF2 excretion into the urine. Cell Tissue Res. 2010;339(3):639-647. DOI:10.1007/s00441-009-0913-8; Huang JX, Blaskovich MA, Cooper MA. Cell- and biomarker-based assays for predicting nephrotoxicity. Expert Opin Drug Metab Toxicol. 2014;10(12):1621-1635. DOI:10.1517/17425255.2014.967681; Jacobs RA, Meinild AK, Nordsborg NB, Lundby C. Lactate oxidation in human skeletal muscle mitochondria. Am J Physiol Endocrinol Metab. 2013;304(7):E686-94. DOI:10.1152/ajpendo.00476.2012; Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol. 2008;48:463-493. DOI:10.1146/annurev.pharmtox.48.113006.094615; Polyanska M, Arner A, Malmquist U, Uvelius B. Lactate dehydrogenase activity and isoform distribution in the rat urinary bladder: effects of outlet obstruction and its removal. J Urol. 1993;150(2 Pt 1):543-545. DOI:10.1016/s0022-5347(17)35543-x; Амдий Р.Э., Аль-Шукри С.Х. Связь между уродинамическими показателями и функцией почек у больных доброкачественной гиперплазией предстательной железы. Урологические ведомости. 2012;2(1):12-15. DOI:10.17816/uroved2112-15; Rex N, Melk A, Schmitt R. Cellular senescence and kidney aging. Clin Sci (Lond). 2023;137(24):1805-1821. DOI:10.1042/CS20230140; Lu CH, Wu HHH, Lin TP, Huang YH, Chung HJ, Kuo JY, Huang WJ, Lu SH, Chang YH, Lin ATL. Is intravesical prostatic protrusion a risk factor for hydronephrosis and renal insufficiency in benign prostate hyperplasia patients? J Chin Med Assoc. 2019;82(5):381-384. DOI:10.1097/JCMA.0000000000000088; Luis-Lima S, Escamilla-Cabrera B, Negrín-Mena N, Estupiñán S, Delgado-Mallén P, Marrero-Miranda D, González-Rinne A, Miquel-Rodríguez R, Cobo-Caso MÁ, Hernández-Guerra M, Oramas J, Batista N, Aldea-Perona A, Jorge-Pérez P, González-Alayón C, Moreno-Sanfiel M, González-Rodríguez JA, Henríquez L, Alonso-Pescoso R, Díaz-Martín L, González-Rinne F, Lavín-Gómez BA, Galindo-Hernández J, Sánchez-Gallego M, González-Delgado A, Jiménez-Sosa A, Torres A, Porrini E. Chronic kidney disease staging with cystatin C or creatinine-based formulas: flipping the coin. Nephrol Dial Transplant. 2019;34(2):287-294. DOI:10.1093/ndt/gfy086; Alaini A, Malhotra D, Rondon-Berrios H, Argyropoulos CP, Khitan ZJ, Raj DSC, Rohrscheib M, Shapiro JI, Tzamaloukas AH. Establishing the presence or absence of chronic kidney disease: Uses and limitations of formulas estimating the glomerular filtration rate. World J Methodol. 2017;7(3):73-92. DOI:10.5662/wjm.v7.i3.73; Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant. 2005;20(4):707-711. DOI:10.1093/ndt/gfh719; Geißer D, Hetzel L, Westenfeld R, Boege F. Questionable Validity of Creatinine-Based eGFR in Elderly Patients but Cystatin C Is Helpful in First-Line Diagnostics. Geriatrics (Basel). 2023;8(6):120. DOI:10.3390/geriatrics8060120; Клинические рекомендации «Острое повреждение почек». Cсылка активна на 11.09.2023. https://rusnephrology.org/wp-content/uploads/2020/12/AKI_final.pdf.; https://www.urovest.ru/jour/article/view/956
-
13Academic Journal
Authors: A. I. Volnukhin, D. Yu. Pushkar, V. A. Malkhasyan, А. И. Волнухин, Д. Ю. Пушкарь, В. А. Малхасян
Source: Urology Herald; Том 12, № 4 (2024); 23-33 ; Вестник урологии; Том 12, № 4 (2024); 23-33 ; 2308-6424 ; 10.21886/2308-6424-2024-12-4
Subject Terms: интермиттирующая катетеризация, benign prostatic hyperplasia, bladder drainage, intermittent catheterization, доброкачественная гиперплазия предстательной железы, дренирование мочевого пузыря
File Description: application/pdf
Relation: https://www.urovest.ru/jour/article/view/917/585; Desgrandchamps F, De La Taille A, Doublet JD; RetenFrance Study Group. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. BJU Int. 2006;97(4):727-733. DOI:10.1111/j.1464-410X.2006.06109.x; Fitzpatrick JM, Desgrandchamps F, Adjali K, Gomez Guerra L, Hong SJ, El Khalid S, Ratana-Olarn K; Reten-World Study Group. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia. BJU Int. 2012;109(1):88-95. DOI:10.1111/j.1464-410X.2011.10430.x; Малхасян В.А., Котов С.В., Мамаев И.Э., Беломытцев С.В., Перов Р.А., Пульбере С.А., Волнухин А.И., Пушкарь Д.Ю. Эффективность и безопасность интермиттирующей катетеризации для купирования острой задержки мочи: проспективное сравнительное рандомизированное исследование. Урология. 2022;(6):9-15. DOI:10.18565/urology.2022.6.9-15; Пушкарь Д.Ю., Малхасян В.А., Ходырева Л.А., Раснер П.И., Куприянов Ю.А., Дударева А.А., Семенякин И.В., Енгай В.А., Зингеренко М.Б., Зинухов А.Ф., Мамаев И.Э., Ответчиков И.Н., Редькович В.И., Сулейманов С.И., Тахирзаде Т.Б., Тедеев В.В., Трушкин Р.Н., Цыганов С.В., Мотин П.И., Ласский И.А. Анализ и оптимизация медицинской помощи пациентам с острой задержкой мочеиспускания, поступающим в стационары г. Москвы. Экспериментальная и клиническая урология. 2016;(2):4-7. eLIBRARY ID: 29899533; EDN: ZEHOUJ; Зимичев А.А., Виноградов Д.С., Тарасов И.В., Гусев Д.О., Почивалов А.С., Мирзоев Д.Д. Современное состояние проблемы выбора метода деривации мочи у пациентов с острой задержкой мочеиспускания. Аспирантский вестник Поволжья. 2020;20(5-6):143-150. DOI:10.17816/2072-2354.2020.20.3.143-150; Delivering quality health services: a global imperative for universal health coverage. Geneva: World Health Organization, Organisation for Economic Co-operation and Development, and The World Bank; 2018.; Yılmaz B, Akkoç Y, Alaca R, Erhan B, Gündüz B, Yıldız N, Gök H, Köklü K, Cınar E, Alemdaroğlu E, Ersöz M, Karapolat H, Demir Y, Bardak AN, Turna I, Catalbaş N, Güneş S, Tunç H. Intermittent catheterization in patients with traumatic spinal cord injury: obstacles, worries, level of satisfaction. Spinal Cord. 2014;52(11):826-830. DOI:10.1038/sc.2014.134; Hakvoort RA, Nieuwkerk PT, Burger MP, Emanuel MH, Roovers JP. Patient preferences for clean intermittent catheterisation and transurethral indwelling catheterisation for treatment of abnormal postvoid residual bladder volume after vaginal prolapse surgery. BJOG. 2011;118(11):1324-1328. DOI:10.1111/j.1471-0528.2011.03056.x; Abidfaheem T, Lee K. Comparison of health related quality of life and health related outcomes among male patients with spinal cord injury with indwelling vs intermittent bladder catheterization - A pilot study. International Journal of Research in Pharmaceutical Sciences. 2020;11:2537-2542. DOI:10.26452/ijrps.v11iSPL4.4150; Chapple A, Prinjha S, Salisbury H. How users of indwelling urinary catheters talk about sex and sexuality: a qualitative study. Br J Gen Pract. 2014;64(623):e364-e371. DOI:10.3399/bjgp14X680149; Amarenco G, Guinet A, Jousse M, Verollet D, Ismael SS. Pencil and paper test: a new tool to predict the ability of neurological patients to practice clean intermittent self-catheterization. J Urol. 2011;185(2):578-582. DOI:10.1016/j.juro.2010.09.106; Малхасян В.А., Геворкян Р.Р., Семенякин И.В., Пушкарь Д.Ю. Оптимальный метод дренирования мочевого пузыря у пациентов с острой задержкой мочеиспускания. Вопросы урологии и андрологии. 2017;5(2):17-21. DOI:10.20953/2307-6631-2017-2-17-21; Mitsui T, Minami K, Furuno T, Morita H, Koyanagi T. Is suprapubic cystostomy an optimal urinary management in high quadriplegics?. A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur Urol. 2000;38(4):434-438. DOI:10.1159/000020320; James R, Frasure HE, Mahajan ST. Urinary catheterization may not adversely impact quality of life in multiple sclerosis patients. ISRN Neurol. 2014;2014:167030. DOI:10.1155/2014/167030; Culha Y, Acaroglu R. The Effect of Video-Assisted Clean Intermittent Catheterization Training on Patients' Practical Skills and Self-Confidence. Int Neurourol J. 2022;26(4):331-341. DOI:10.5213/inj.2244166.083; Girotti ME, MacCornick S, Perissé H, Batezini NS, Almeida FG. Determining the variables associated to clean intermittent self-catheterization adherence rate: one-year follow-up study. Int Braz J Urol. 2011;37(6):766-772. DOI:10.1590/s1677-55382011000600013; Parsons BA, Narshi A, Drake MJ. Success rates for learning intermittent self-catheterisation according to age and gender. Int Urol Nephrol. 2012;44(4):1127-1131. DOI:10.1007/s11255-012-0136-x; https://www.urovest.ru/jour/article/view/917
-
14Academic Journal
Authors: Sh. A. Abbosov, A. B. Shomarufov, D. R. Aminova, Ш. А. Аббосов, А. Б. Шомаруфов, Д. Р. Аминова
Source: Urology Herald; Том 12, № 4 (2024); 5-13 ; Вестник урологии; Том 12, № 4 (2024); 5-13 ; 2308-6424 ; 10.21886/2308-6424-2024-12-4
Subject Terms: контрактура шейки мочевого пузыря, benign prostatic hyperplasia, balloon dilation, transrectal ultrasound, доброкачественная гиперплазия предстательной железы, баллонная дилатация
File Description: application/pdf
Relation: https://www.urovest.ru/jour/article/view/907/574; Xiang P, Guan D, Du Z, Hao Y, Yan W, Wang Y, Liu Y, Liu D, Ping H. Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. Eur Radiol. 2021;31(7):4929-4946. DOI:10.1007/s00330-020-07663-2; Frendl DM, Chen YW, Chang DC, Kim MM. A Claims Based Assessment of Reoperation and Acute Urinary Retention after Ambulatory Transurethral Surgery for Benign Prostatic Hyperplasia. J Urol. 2021;205(2):532-538. DOI:10.1097/JU.0000000000001390; Arcaniolo D, Manfredi C, Veccia A, Herrmann TRW, Lima E, Mirone V, Fusco F, Fiori C, Antonelli A, Rassweiler J, Liatsikos E, Porpiglia F, De Sio M, Autorino R; EAU Section of Uro-Technology (ESUT) Research Group. Bipolar endoscopic enucleation versus bipolar transurethral resection of the prostate: an ESUT systematic review and cumulative analysis. World J Urol. 2020;38(5):1177-1186. DOI:10.1007/s00345-019-02890-9; Sun F, Sun X, Shi Q, Zhai Y. Transurethral procedures in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications. Medicine (Baltimore). 2018;97(51):e13360. DOI:10.1097/MD.0000000000013360; Zhang Y, Fu C, Wang J, Wu P, Chen X, Hou H, Song X, Cheng W, Wang J, Liu M. Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser. J Vis Exp. 2020;(159). DOI:10.3791/60532; Enikeev D, Rapoport L, Gazimiev M, Allenov S, Inoyatov J, Taratkin M, Laukhtina E, Sung JM, Okhunov Z, Glybochko P. Monopolar enucleation versus transurethral resection of the prostate for small- and mediumsized (< 80 cc) benign prostate hyperplasia: a prospective analysis. World J Urol. 2020;38(1):167-173. DOI:10.1007/s00345-019-02757-z; Reale G, Marchioni M, Altieri V, Greco F, De Nunzio C, Destefanis P, Ricciardulli S, Bergamaschi F, Fasolis G, Varvello F, Voce S, Palmieri F, Divan C, Malossini G, Oriti R, Tuccio A, Ruggera L, Tubaro A, Delicato G, Laganà A, Dadone C, De Rienzo G, Ditonno A, Frattini A, Pucci L, Carrino M, Montefiore F, Germani S, Miano R, Schips L, Rabito S, Ferrari G, Cindolo L. Operative profile, safety and functional outcomes after GreenLight laser prostate surgery: results from a 12 months follow-up multicenter Italian cohort analyses. Minerva Urol Nefrol. 2020;72(5):622-628. DOI:10.23736/S0393-2249.20.03597-3; Ibrahimi A, Ziani I, El Boukili El Makhoukhi Z, El Sayegh H, Benslimane L, Nouini Y. Transurethral resection syndrome: A rare complication of intraperitoneal bladder perforation during transurethral resection of bladder tumor. Urol Case Rep. 2020;34:101465. DOI:10.1016/j.eucr.2020.101465; Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol. 2006;50(5):969-979; discussion 980. DOI:10.1016/j.eururo.2005.12.042; Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, Speakman MJ, Stief CG. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010;58(3):384-397. DOI:10.1016/j.eururo.2010.06.005; Grechenkov A, Sukhanov R, Bezrukov E, Butnaru D, Barbagli G, Vasyutin I, Tivtikyan A, Rapoport L, Alyaev Y, Glybochko P. Risk factors for urethral stricture and/or bladder neck contracture after monopolar transurethral resection of the prostate for benign prostatic hyperplasia. Urologia. 2018;85(4):150-157. DOI:10.1177/0391560318758195; Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, Lack N, Stief CG; Urology Section of the Bavarian Working Group for Quality Assurance. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246-249. DOI:10.1016/j.juro.2008.03.058; Аббосов Ш.А., Сорокин Н.И., Кадрев А.В., Шомаруфов А.Б., Нестерова О.Ю., Акилов Ф.А., Камалов А.А. Предикторы развития склероза шейки мочевого пузыря после трансуретральных вмешательств на предстательной железе. Урология. 2021;(5):73-77. DOI:10.18565/urology.2021.5.73-77; Barbalias D, Lappas G, Ravazoula P, Liourdi D, Kyriazis I, Liatsikos E, Kallidonis P. Evaluation of the Distribution of Paclitaxel After Application of a Paclitaxel-Coated Balloon in the Rabbit Urethra. J Endourol. 2018;32(5):381-386. DOI:10.1089/end.2017.0935; Рева И.А., Живов А.В., Берников А.Н., Пушкарь Д.Ю. Факторы риска развития и методики коррекции послеоперационного стеноза везикоуретрального анастомоза (обзор литературы). Онкоурология. 2017;13(2):104-112. DOI:10.17650/1726-9776-2017-13-2-104-112; Favre GA, Alfieri AG, Gil Villa SA, Tobia I, Giudice CR. Bulbomembranous Urethral Strictures Repair After Surgical Treatment of Benign Prostatic Hyperplasia. Experience From a Latin American Referral Centre. Urology. 2021;147:281-286. DOI:10.1016/j.urology.2020.08.085; Abbosov SA, Sorokin NI, Shomarufov AB, Kadrev AV, Ugli N, Khusniddin Z, Mukhtarov ST, Akilov FA, Kamalov AA. Bladder Neck Contracture as a Complication of Prostate Surgery. Alternative Treatment Methods and Prospects (Literature Review). Urological Science. 2022;33(2):49-55. DOI:10.4103/UROS.UROS_127_21; Steenkamp JW, Heyns CF, de Kock ML. Internal urethrotomy versus dilation as treatment for male urethral strictures: a prospective, randomized comparison. J Urol. 1997;157(1):98-101. PMID: 8976225.; Vicente J, Salvador J, Caffaratti J. Endoscopic urethrotomy versus urethrotomy plus Nd-YAG laser in the treatment of urethral stricture. Eur Urol. 1990;18(3):166-168. DOI:10.1159/000463901; Lee YH, Chiu AW, Huang JK. Comprehensive study of bladder neck contracture after transurethral resection of prostate. Urology. 2005;65(3):498-503; discussion 503. DOI:10.1016/j.urology.2004.10.082; Мухтаров Ш.Т., Насиров Ф.Р., Бахадирханов М.М., Уралова Н.Д., Акилов Ф.А., Мирхамидов Д.Х., Шомаруфов А.Б., Аббосов Ш.А., Касимов С.С. Оценка эффективности и безопасности эндоскопического лечения облитерации бульбарно-мембранозного отдела уретры. Вестник урологии. 2022;10(4):79-87. DOI:10.21886/2308-6424-2022-10-4-79-87; Abbosov ShA, Sorokin NI, Shomarufov AB, Kadrev AV, Mikheev KV, Fozilov AA, Nadjimitdinov YS, Ohobotov DA, Giyasov ShI, Mukhtarov ShT, Akilov FA, Kamalov AA. Assessment of the Balloon Dilation Efficiency in Bladder Neck Contracture after Transurethral Interventions on the Prostate. Urological Science. 2022;33(3):130-135. DOI:10.4103/UROS.UROS_148_21; Ramchandani P, Banner MP, Berlin JW, Dannenbaum MS, Wein AJ. Vesicourethral anastomotic strictures after radical prostatectomy: efficacy of transurethral balloon dilation. Radiology. 1994;193(2):345-349. DOI:10.1148/radiology.193.2.7972741; Ishii G, Naruoka T, Kasai K, Hata K, Omono H, Suzuki M, Kimura T, Egawa S. High pressure balloon dilation for vesicourethral anastomotic strictures after radical prostatectomy. BMC Urol. 2015;15:62. DOI:10.1186/s12894-015-0059-9; Аббосов Ш.А., Охоботов Д.А., Сорокин Н.И., Шомаруфов А.Б., Шапаров Б.М., Наджимитдинов Я.С., Мухтаров Ш.Т., Акилов Ф.А., Камалов А.А. Оценка эффективности баллонной дилатации рубцового сужения шейки мочевого пузыря после трансуретральных вмешательств на предстательной железе (предварительные результаты). Вестник урологии. 2021;9(1):5-13. DOI:10.21886/2308-6424-2021-9-1-5-13; Vyas JB, Ganpule AP, Muthu V, Sabnis RB, Desai MR. Balloon dilatation for male urethral strictures “revisited”. Urol Ann. 2013;5(4):245-248. DOI:10.4103/0974-7796.120296; Xie TP, Huang XB, Xu QQ, Ye HY, Yang QY, Wang XF. [Balloon dilation by B ultrasound monitoring for treatment of urethral stricture: 5 case reports]. Beijing Da Xue Xue Bao Yi Xue Ban. 2014;46(4):657-658. (In Chinese). PMID: 25131490.; https://www.urovest.ru/jour/article/view/907
-
15Academic Journal
Authors: Suslov, A.S.
Source: МЕДИЦИНА НЕВІДКЛАДНИХ СТАНІВ; Том 16, № 4 (2020); 110-114
МЕДИЦИНА НЕОТЛОЖНЫХ СОСТОЯНИЙ; Том 16, № 4 (2020); 110-114
EMERGENCY MEDICINE; Том 16, № 4 (2020); 110-114Subject Terms: benign prostatic hyperplasia, surgery, transvesical prostatectomy, analgesia, epidural analgesia, 03 medical and health sciences, 0302 clinical medicine, доброякісна гіперплазія передміхурової залози, хірургія, черезміхурова простатектомія, аналгезія, епідуральна аналгезія, доброкачественная гиперплазия предстательной железы, хирургия, чреспузырная простатэктомия, анальгезия, эпидуральная анальгезия, 3. Good health
File Description: application/pdf
-
16Academic Journal
Source: Хирургия. Восточная Европа. :357-366
Subject Terms: 03 medical and health sciences, benign prostatic hyperplasia, insulin, 0302 clinical medicine, лептин, аполипопротеины, инсулин, доброкачественная гиперплазия предстательной железы, leptin, apolipoproteins, metabolic syndrome, 3. Good health, метаболический синдром
-
17Academic Journal
Authors: Volkov, S. N., Mikheev, R. K., Grigoryan, O. R., Tereshchenko, V. I., Stepanchenko, V. S., Andreeva, E. N., Волков, С. Н., Михеев, Р. К., Григорян, О. Р., Терещенко, В. И., Степанченко, В. С., Андреева, Е. Н.
Subject Terms: BENIGN PROSTATIC HYPERPLASIA, BODY MASS INDEX, COMPARATIVE ANALYSIS, UROLOGY, SURGERY, ДОБРОКАЧЕСТВЕННАЯ ГИПЕРПЛАЗИЯ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, ИНДЕКС МАССЫ ТЕЛА, КОРРЕЛЯЦИОННЫЙ АНАЛИЗ, УРОЛОГИЯ, ХИРУРГИЯ
File Description: application/pdf
Relation: Уральский медицинский журнал. 2023. Т. 22, № 3.; http://elib.usma.ru/handle/usma/14605
Availability: http://elib.usma.ru/handle/usma/14605
-
18Academic Journal
Authors: S. V. Popov, R. G. Huseynov, D. A. Saydulaev, S. V. Sadovnikov, Yu. V. Kisil, K. V. Sivak, N. S. Bunenkov, V. V. Perepelitsa, A. S. Ulitina, T. A. Lelyavina, С. В. Попов, Р. Г. Гусейнов, Д. А. Сайдулаев, С. В. Садовников, Ю. В. Кисиль, К. В. Сивак, Н. С. Буненков, В. В. Перепелица, А. С. Улитина, Т. А. Лелявина
Source: Russian Journal of Transplantology and Artificial Organs; Том 25, № 2 (2023); 15-25 ; Вестник трансплантологии и искусственных органов; Том 25, № 2 (2023); 15-25 ; 1995-1191
Subject Terms: трансплантация почки, benign prostatic hyperplasia, kidney transplantation, доброкачественная гиперплазия предстательной железы
File Description: application/pdf
Relation: https://journal.transpl.ru/vtio/article/view/1603/1467; https://journal.transpl.ru/vtio/article/view/1603/1486; https://journal.transpl.ru/vtio/article/downloadSuppFile/1603/1265; Годовой отчет о трансплантологии в Европе за 2019 год. https://www.eurotransplant.org/wp-content/uploads/2020/06/AnnualReport-2019.pdf.; Готье СВ, Хомяков СМ. Донорство и трансплантация органов в Российской Федерации в 2018 году. XII сообщение Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2019; 21 (3): 7–32. https://doi.org/10.15825/1995-1191-2019.; Кабанова СА, Богопольский ПМ. Пересадка почки: история, итоги и перспективы. Трансплантология. 2015; (2): 49–58.; Султанов ПК, Хаджибаев ФА, Эргашев ДН, Исматов АА. Анализ осложнений после трансплантации почки. Вестник экстренной медицины. 2021; 14 (1): 55–63.; Dos Santos Mantovani M, Coelho de Carvalho N, Archangelo TE, Modelli de Andrade LG, Pires Ferreira Filho S, de Souza Cavalcante R et al. Frailty predicts surgical complications after kidney transplantation. A propensity score matched study. PLoS One. 2020 Feb 26; 15 (2): e0229531.; Bessede T, Hammoudi Y, Bedretdinova D, Parier B, Francois H, Durrbach A, Benoit G. Preoperative Risk Factors Associated With Urinary Complications After Kidney Transplantation. Transplant Proc. 2017 Nov; 49 (9): 2018–2024.; Hickman LA, Sawinski D, Guzzo T, Locke JE. Urologic malignancies in kidney transplantation. Am J Transplant. 2018 Jan; 18 (1): 13–22.; Shimizu T, Sugihara T, Kamei J, Takeshima S, Kinoshita Y, Kubo T et al. Predictive factors and management of urinary tract infections after kidney transplantation: a retrospective cohort study. Clin Exp Nephrol. 2021 Feb; 25 (2): 200–206.; Thuret R, Timsit MO, Kleinclauss F. Chronic kidney disease and kidney transplantation. Prog Urol. 2016 Nov; 26 (15): 882–908.; Billis A, Freitas LLL, Costa LBE, Barreto IS, Botega AAR, Pereira TA, D’Ancona CA. Lower Urinary Tract Symptoms Due to Xanthoma of the Prostate After Kidney Transplantation: A Case Report. Transplant Proc. 2020 Nov; 52 (9): 2736–2738.; Frascà GM, Brigante F, Volpe A, Cosmai L, Gallieni M, Porta C. Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines. J Nephrol. 2019 Feb; 32 (1): 57–64.; Tan JHS, Bhatia K, Sharma V, Swamy M, van Dellen D, Dhanda R, Khambalia H. Enhanced recovery after surgery recommendations for renal transplantation: guidelines. Br J Surg. 2022 Dec 13; 110 (1): 57–59.; Thuret R, Kleinclauss F, Terrier N, Karam G, Timsit MO. Challenges in renal transplantation. Prog Urol. 2016 Nov; 26 (15): 1001–1044. 14. Maggiore U, Abramowicz D, Budde K. Renal transplantation in the elderly. Transplant Rev (Orlando). 2015 Oct; 29 (4): 191–192.; Rodríguez Faba O, Boissier R, Budde K, Figueiredo A, Taylor CF, Hevia V et al. European Association of Urology Guidelines on Renal Transplantation: Update 2018. Eur Urol Focus. 2018 Mar; 4 (2): 208–215.; Cheung CY, Tang SCW. An update on cancer after kidney transplantation. Nephrol Dial Transplant. 2019 Jun 1; 34 (6): 914–920.; Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tractsymptoms: prevalence and incident rates. Urol Clin North Am. 2016; 43: 289.; De Oliveira Marinho AC, TavaresdaSilva E, Bastos CA, Roseiro A, Parada B, Retroz E et al. Acute Urinary Retention After Kidney Transplant: Effect on Graft Function, Predictive Factors, and Treatment. Transplant Proc. 2021 Jul-Aug; 53 (6): 1933–1938.; Sarier M, Yayar O, Yavuz A, Turgut H, Kukul E. Update on the Management of Urological Problems Following Kidney Transplantation. Urol Int. 2021; 105 (7–8): 541–547.; Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I – Initial Work-up and Medical Management. J Urol. 2021 Oct; 206 (4): 806–817.; Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II – Surgical Evaluation and Treatment. J Urol. 2021 Oct; 206 (4): 818–826.; Касян ГР, Ходырева ЛА, Дударева АА и др. Комбинированное лечение симптомов нижних мочевых путей у мужчин. Медицинский совет. 2016; 5: 84–90.; Seo JH, Han JS, Lee Y, Myong JP, Ha US. Fall risk related to subtype-specific alpha-antagonists for benign prostatic hyperplasia: a nationwide Korean populationbased cohort study. World J Urol. 2022 Dec; 40 (12): 3043–3048.; Пушкарь ДЮ, Раснер ПИ, Харчилава РР. Российские клинические рекомендации с современными данными ведущих российских специалистов. Симптомы нижних мочевыводящих путей и доброкачественная гиперплазия предстательной железы. Урология. 2016; (2, прилож.): 4–19.; Раснер ПИ, Газимиев МА, Гаджиева ЗК и др. Расстройства мочеиспускания у мужчин: методические рекомендации, № 6. М.: АБВ-пресс, 2017; 35.; Павлов ВН, Галимзянов ВЗ, Казихинуров АА, Пушкарев АМ, Загитов АР, Казихинурова АА, Шарипов ИР. Симптомы нижних мочевыводящих путей и доброкачественная гиперплазия предстательной железы: учебное пособие. Уфа: БГМУ, 2018; 86.; Foster HE, Dahm P, Kohler TS et al. Surgical management of lower urinary tract symptom sattributed to benign prostatic hyperplasia: AUA Guideline amendment 2019. J Urol. 2019; 202: 592.; Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective α1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2013; 189 (1 Suppl): S122–S128.; Homma Y, Kawabe K, Tsukamoto T et al. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. Int J Urol. 1996; 3: 261–266.; Debruyne F, Boyle P, Calais Da Silva F et al. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients – PERMAL study subset analysis. Eur Urol. 2004; 45: 773–779.; Razek M, Abolyosr A, Mhammed O, Fathi A, Talaat M, Hassan A. Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. World J Urol. 2022. Aug; 40 (8): 2063–2070.; Lukacs B, Grange JC, Comet D. One-year follow-up of 2829 patients with moderate to severe lower urinarytract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice Urology. 2000; 55: 540–546.; Barendrecht MM, Abrams P, Schumacher H, de a Rosette JJ, Michel MC. Do α1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn. 2008; 27: 226–230.; Fusco F, Creta M, De Nunzio C et al. Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans. BMC Urol. 2018; 18: 15.; Gul ZG, Kaplan SA. BPH: why do patients fail medical therapy? Curr Urol Rep. 2019; 20: 40.; La Vignera S, Aversa A, Cannarella R, Condorelli RA, Duca Y, Russo GI, Calogero AE. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opin Pharmacother. 2021 Feb; 22 (2): 179–189.; Alcaraz A, CastroDíaz D, Gacci M, Salonia A, Ficarra V, CarballidoRodríguez J et al. Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-toSevere LUTS-BPH Patients: Results of a Paired Matched Clinical Study. On Behalf Of The Qualiprost Study Group. J Clin Med. 2022 Jun 22; 11 (13): 3615.; Bauer SR, Walter LC, Ensrud KE, Suskind AM, Newman JC, Ricke WA et al. Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. JAMA Netw Open. 2021 Nov 1; 4 (11): e2134427.; Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA. Comparative analysis of the effectiveness of early and delayed initiation of combined DRUG therapy for bph. Urologiia. 2021 May; (2): 27–30.; Gravas S, Cornu JN, Gacci M et al. EAU guidelines on management of non-neurogenic male LUTS. Presented at 2020 EAU Annual Congress, Amsterdam, Arnhem, The Netherlands. Available at http://uroweb.org/guidelines/compilations-of-all-guidelines/.; Anderson BB, Pariser JJ, Helfand BT. Comparison of Patients Undergoing PVP Versus TURP for LUTS/BPH. Curr Urol Rep. 2015 Aug; 16 (8): 55.; Drouin S, Defortescu G, Prudhomme T, Culty T, Verhoest G, Doerfler A et al. Lower urinary tract symptoms and urinary incontinence in renal transplant recipients and candidates: The French guidelines from CTAFU. Prog Urol. 2021 Jan; 31 (1): 45–49.; Checcucci E, Veccia A, De Cillis S, Piramide F, Volpi G, Amparore D et al. New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: A Systematic Review and Analysis of Comparative Outcomes. Uro-technology and SoMe Working Group of the Young Academic Urologists Working Party of the European Association of Urology and of the Lower Tract and Research Group of the European Section of Uro-technology. Eur Urol Open Sci. 2021 Sep 22; 33: 28–41.; Righetto M, Mancini M, Modonutti D, Calpista A, Beltrami P, Dal Moro F. Patients with renal transplant and moderate-to-severe LUTS benefit from urodynamic evaluation and early transurethral resection of the prostate. World J Urol. 2021 Dec; 39 (12): 4397–4404.; Sarier M, Tekin S, Duman İ, Yuksel Y, Demir M, Alptekinkaya F et al. Results of transurethral resection of the prostate in renal transplant recipients: a single center experience. World J Urol. 2018 Jan; 36 (1): 99–103.; Rassweiler J, Teber D, Kuntz R et al. Complications of transurethral resection of the prostate (TURP) dincidence, management, and prevention. Eur Urol. 2006; 50: 969.; Liu Z, Li YW, Wu WR et al. Long-term clinicale fficacy and safety profile of transurethral resection of prostate versus plasma kinetic resection of the prostate for benign prostatic hyperplasia. Urology. 2017; 103: 198.; Friedl A, Schneeweiss J, Stangl K et al. The adjustable transobturator male system in stress urinary incontinence after transurethral resection of the prostate. Urology. 2017; 109: 184.; Boston Scientific Corporation: Intended use. Rezum Instruction for Use, 10-2019; 5.; Dixon CM, Rijo Cedano E, Mynderse LA et al. Transurethral convective water vapor as atreatment for lower urinary tract symptom-atology due to benign prostatic hyperplasiausing the Rezum(R) system: evaluation of acuteablative capabilities in the human prostate. Res Rep Urol. 2015; 7: 13.; Bouza C, Lopez T, Magro A et al. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol. 2006; 6: 14.; McVary KT, Rogers T, Mahon J et al. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia? J Sex Med. 2018; 15: 1728.; National Institute for Health and Care Excellence: Rezum for treating lower urinary tractsymptoms secondary to benign prostatic hyperplasia (24 June 2020). NICE Guideline No. MTG49.; Mynderse LA, Roehrborn CG, Partin AW et al. Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. J Urol. 2011; 185: 1804.; Gravas S, Cornu JN, Gacci M et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Arnhem, The Netherlands: EAU Guidelines Office. 2020.; McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal therapy for lower urinarytract symptoms associated with benign prostatichyperplasia: 4-year results from randomized controlled study. Urology. 2019; 126: 171.; McVary KT, Roehrborn CG. Three-year out-comes of the prospective, randomized controlled Rezum System Study: convective radio frequency thermal therapy for treatment of lower urinarytract symptoms due to benign prostatic hyperplasia. Urology. 2018; 111: 1.; U.S. Food and Drug Administration: Select Up-dates for Guidance for the Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH): Draft Guidance for Industry and Food and Drug Administration Staff (July 14, 2020).; Roehrborn CG, Wilson TH, Black LK. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. J Urol. 2012; 187: 1732.; Miller LE, Chughtai B, Dornbier RA et al. Surgical reintervention rate after prostatic urethral lift: systematic review and meta-analysis involving over 2,000 patients. J Urol. 2020; 204: 1019.; Roehrborn CG, Barkin J, Gange SN et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017; 24: 8802.; Zlotta AR, Giannakopoulos X, Maehlum O et al. Longterm evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol. 2003; 44: 89.; Rosario DJ, Phillips JT, Chapple CR. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails. J Urol. 2007; 177: 1047.; Hill B, Belville W, Bruskewitz R et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol. 2004; 171: 2336.; Gupta N, Rogers T, Holland B et al. Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol. 200; 405: 2018.; Malde S, Rajagopalan A, Patel N et al. Potassium-titanyl-phosphate laser photoselective vaporization for benign prostatic hyperplasia: 5-year follow-up from a district general hospital. J Endourol. 2012; 26: 878.; Lee HE, Kim B, Yoon HS, Suh J, Oh SJ. Outcome of Patients With Elevated Prostate-Specific Antigen and Lower Urinary Tract Symptoms Receiving Holmium Laser Enucleation of the Prostate. Int Neurourol J. 2022 Sep; 26 (3): 248–257.; Takeuchi Y, Sawada Y, Watanabe S, NiItsu Y, Sekido N. Age-specific effect of transurethral holmium laser enucleation of the prostate on overactive bladder in men with benign prostatic hyperplasia: An investigation using an overactive bladder symptom score. Low Urin Tract Symptoms. 2022 Dec 11.; Nohara T, Matsuyama S, Shima T, Kawaguchi S, Seto C. Holmium Laser Enucleation of the Prostate With Percutaneous Nephrostomy Into the Transplanted Kidney in Patient With Severe Benign Prostatic Hyperplasia With Vesicoureteral Reflux – A Case Report. Urol Case Rep. 2015 Dec 10; 4: 33–35.; Prudhomme T, Marquette T, Péré M. Benign Prostatic Hyperplasia Endoscopic Surgical Procedures in Kidney Transplant Recipients: A Comparison Between Holmium Laser Enucleation of the Prostate, GreenLight Photoselective Vaporization of the Prostate, and Transurethral Resection of the Prostate. J Endourol. 2020 Feb; 34 (2): 184–191.; Baboudjian M, Fourmarier M, GondranTellier B, Pradere B, Userovici M, Alegorides C, Barry Delongchamps N. Head-to-head comparison of prostatic urethral lift and water vapor thermal therapy for the treatment of symptomatic benign prostatic hyperplasia: a real-life study. Int Urol Nephrol. 2021 Sep; 53 (9): 1757–1763.; Alexander CE, Scullion MM, Omar MI, Yuan Y, Mamoulakis C, N’Dow JM et al. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev. 2019 Dec 3; 12 (12): CD009629.; Mamoulakis C, Ubbink DT, de la Rosette JJ. Bipolar versus monopolar transurethral resection of the prostate: A systematic review and meta-analysis of randomized controlled trials. Eur Urol. 2009; 56: 798–809. doi:10.1016/j.eururo.2009.06.037.; Ahyai SA, Gilling P, Kaplan SA et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010; 58: 384–397.; Burke N, Whelan JP, Goeree L et al. Systematic review and meta-analysis of transurethral resection of the prostate vs. minimally invasive procedures for the treatment of benign prostatic obstruction. Urology. 2010; 75: 1015–1022.; Omar MI, Lam TBL, Cameron A et al. Systematic review and meta-analysis of the clinical effectiveness of bipolar compared to monopolar transurethral resection of the prostate. BJU Int. 2014; 113: 24–35.; Cornu JN, Ahyai S, Bachmann A et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: An update. Eur Urol. 2015; 67: 1066–1096.; Mamoulakis C, Sofras F, de la Rosette J et al. Bipolar vs. monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev. 2014; 1: CD009629.; Taylor BL, Jaffe WI. Electrosurgical transurethral resection of the prostate and transurethral incision of the prostate (monopolar techniques). Can J Urol. 2015 Oct; 22 Suppl 1: 24–29.; Sarıer M, Duman İ, Demir M, Yüksel Y, Emek M, Kukul E. The outcomes of transurethral incision/resection of the prostate (TUIP/TURP) performed early afterrenal transplantation. Turk J Urol. 2018 Mar; 44 (2): 172–177.; Sarier M, Duman I, Kilic S, Yuksel Y, Demir M, Aslan M et al. Comparative Results of Transurethral Incision with Transurethral Resection of The Prostate in Renal Transplant Recipients with Benign Prostate Hyperplasia. Urol J. 2018 Jul 10; 15 (4): 209–213.; Duty BD, Conlin MJ, Fuchs EF, Barry JM. The current role of endourologic management of renal transplantation complications. Adv Urol. 2013; 2013: 246520.; Cardi A, Palleschi G, Patruno G, Tuffu G, D’Amico FE, De Vico A et al. Robot-assisted simple prostatectomy for treatment of large prostatic adenomas: surgical technique and outcomes from a high-volume robotic centre. World J Urol. 2022 Dec 25.; Law YXT, Chen WJK, Shen L, Chua WJ. Is transurethral needle ablation of prostate out of fashion? Outcomes of single session office-based transurethral needle ablation of prostate in patients with symptomatic benign prostatic hyperplasia. Investig Clin Urol. 2019 Sep; 60 (5): 351–358.; Powell T, Rahman S, Staib L, Bhatia S, Ayyagari R. Operator Learning Curve for Prostatic Artery Embolization and Its Impact on Outcomes in 296 Patients. Cardiovasc Intervent Radiol. 2022 Dec 1.; Goyal P, Salem R, Mouli SK. Controversies in Prostate Artery Embolization: Future Best Practice. Semin Intervent Radiol. 2022 Dec 20; 39 (6): 562–570.; GondranTellier B, McManus R, Sichez PC, Akiki A, Gaillet S, Toledano H et al. Efficacy and Safety of Surgery for Benign Prostatic Obstruction in Patients with Preoperative Urinary Catheter. J Endourol. 2021 Jan; 35 (1): 102–108.; Яремин БИ, Харитонов БИ, Миронов АА, Масликова УВ, Александрова ВЭ. Трансплантация почки – поиск оптимальной хирургической техники. Вестник медицинского института «РЕАВИЗ». 2017; (5): 94–104.; Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020 Apr; 104 (4S1 Suppl 1): S11–S103.; Choudhury S, Haldar B, Pal DK. Spectrum of lower urinary tract symptoms after renal transplant among adult non-urologic anuric patients and their management in a tertiary care center. Urologia. 2022 Feb 3: 3915603211048150. doi:10.1177/03915603211048150.; Клинические рекомендации Европейской ассоциации урологов [Электронный ресурс]. М.: Медконгресс, 2019; 1368.; Интегративная урология. Руководство для врачей / Под ред. П.В. Глыбочко, Ю.Г. Аляева. М.: Медфорум, 2014: 128–239, 314–326.; na P, Baboudjian M, Piana A, Girón I et al. New Generation Pulse Modulation in Holmium:YAG Lasers: A Systematic Review of the Literature and Meta-Analysis. J Clin Med. 2022 Jun 4; 11 (11): 3208.; Perri A, Izzo G, Lofaro D, La Vignera S, Brunetti A, Calogero AE, Aversa A. Erectile Dysfunction after Kidney Transplantation. J Clin Med. 2020 Jun 25; 9 (6): 1991.; Kleinclauss F, Thuret R, Murez T, Timsit MO. Urologic malignancies in renal transplant candidates and recipients. Prog Urol. 2016 Nov; 26 (15): 1094–1113.; Данович МГ. Трансплантация почки. Пер. с англ. под ред. Я.Г. Мойсюка. М.: ГЭОТАР Медиа, 2014; 848.; Latchamsetty KC, Mital D, Jensik S. Use of collagen injections for vesicoureteral reflux in transplanted kidney. Transplant Proc. 2003; 35: 1378.; Li Marzi V, Filocamo MT, Dattolo E. The treatment of fistulae and ureteral stenosis after kidney transplantation. Transplant Proc. 2005; 37: 2516.; Mokos I, Kastelan Z, BasićJukić N, Kes P, Pasini J. Transurethral incision/resection of the prostate (TUIP/ TURP) in operative treatment of repeated bladder outlet obstruction early after kidney transplantation. Acta Clin Croat. 2011 Sep; 50 (3): 381–384.; Védrine N, Nsabimbona B, Soares P, Deteix P, Boiteux JP, Guy L. Transurethral resection or incision of the prostate in the immediate postoperative follow-up of renal transplantation. Prog Urol. 2009 Dec; 19 (11): 845–849.; Gratzke C, Pahde A, Dickmann M, Reich O, Seitz M, Jauch K et al. Predictive factors for urinary retention following kidney transplantation in male patients. Scand J Urol Nephrol. 2012 Feb; 46 (1): 44–47.; Gill BC, Ulchaker JC. Costs of managing benign prostatic hyperplasia in the office and operating room. Curr Urol Rep. 2018; 19: 72.; https://journal.transpl.ru/vtio/article/view/1603
-
19Academic Journal
Authors: Z. M. Akhokhov, R. S. Ismailov, M. I. Kogan, З. М. Ахохов, Р. С. Исмаилов, М. И. Коган
Source: Urology Herald; Том 11, № 3 (2023); 98-107 ; Вестник урологии; Том 11, № 3 (2023); 98-107 ; 2308-6424 ; 10.21886/2308-6424-2023-11-3
Subject Terms: обзор литературы, benign prostatic hyperplasia, prostate cancer, lower urinary tract symptoms, prostate specific antigen, molecular biological markers, ribonucleic acid, review, доброкачественная гиперплазия предстательной железы, рак предстательной железы, симптомы нижних мочевых путей, простатический специфический антиген, молекулярно-биологические маркёры, рибонуклеиновая кислота
File Description: application/pdf
Relation: https://www.urovest.ru/jour/article/view/760/498; Li J, Shi Q, Bai Y, Pu C, Tang Y, Yuan H, Wu Y, Wei Q, Han P. Efficacy and safety of muscarinic antagonists as add-on therapy for male lower urinary tract symptoms. Sci Rep. 2014;4:3948. DOI:10.1038/srep03948; Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016;43(3):289-97. DOI:10.1016/j.ucl.2016.04.001; Аполихин О.И., Сивков А.В., Комарова В.А., Никушина А.А. Болезни предстательной железы в Российской Федерации: статистические данные 2008-2017 гг. Экспериментальная и клиническая урология. 2019;(2):4-13. DOI:10.29188/2222-8543-2019-11-2-4-12.; Zhu C, Wang DQ, Zi H, Huang Q, Gu JM, Li LY, Guo XP, Li F, Fang C, Li XD, Zeng XT. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil Med Res. 2021;8(1):64. DOI:10.1186/s40779-021-00359-8; Platz EA, Joshu CE, Mondul AM, Peskoe SB, Willett WC, Giovannucci E. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol. 2012;188(2):496-501. DOI:10.1016/j.juro.2012.03.125; Garg A, Bansal S, Saha S, Kumar A. Study of correlation of urodynamic profile with symptom scoring and ultrasonographic parameters in patients with benign prostatic hyperplasia. J Family Med Prim Care. 2020;9(1):215-220. DOI:10.4103/jfmpc.jfmpc_698_19; Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59(5):671-81. DOI:10.1016/j.eururo.2011.01.044; Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-54. DOI:10.1016/0092-8674(93)90529-y; McGuire A, Brown JA, Kerin MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 2015;34(1):145-55. DOI:10.1007/s10555-015-9551-7; Гареев И.Ф., Бейлерли О.А. Циркулирующие микроРНК как биомаркеры: какие перспективы? Профилактическая медицина. 2018;21(6):142‑150. DOI:10.17116/profmed201821061142; Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004;432(7014):231-5. DOI:10.1038/nature03049; Broughton JP, Lovci MT, Huang JL, Yeo GW, Pasquinelli AE. Pairing beyond the Seed Supports MicroRNA Targeting Specificity. Mol Cell. 2016;64(2):320-333. DOI:10.1016/j.molcel.2016.09.004; de Rie D, Abugessaisa I, Alam T, Arner E, Arner P, Ashoor H, Åström G, Babina M, Bertin N, Burroughs AM, Carlisle AJ, Daub CO, Detmar M, Deviatiiarov R, Fort A, Gebhard C, Goldowitz D, Guhl S, Ha TJ, Harshbarger J, Hasegawa A, Hashimoto K, Herlyn M, Heutink P, Hitchens KJ, Hon CC, Huang E, Ishizu Y, Kai C, Kasukawa T, Klinken P, Lassmann T, Lecellier CH, Lee W, Lizio M, Makeev V, Mathelier A, Medvedeva YA, Mejhert N, Mungall CJ, Noma S, Ohshima M, Okada-Hatakeyama M, Persson H, Rizzu P, Roudnicky F, Sætrom P, Sato H, Severin J, Shin JW, Swoboda RK, Tarui H, Toyoda H, Vitting-Seerup K, Winteringham L, Yamaguchi Y, Yasuzawa K, Yoneda M, Yumoto N, Zabierowski S, Zhang PG, Wells CA, Summers KM, Kawaji H, Sandelin A, Rehli M; FANTOM Consortium; Hayashizaki Y, Carninci P, Forrest ARR, de Hoon MJL. An integrated expression atlas of miRNAs and their promoters in human and mouse. Nat Biotechnol. 2017;35(9):872-878. DOI:10.1038/nbt.3947; Tanzer A, Stadler PF. Molecular evolution of a microRNA cluster. J Mol Biol. 2004;339(2):327-35. DOI:10.1016/j.jmb.2004.03.065; Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004;5(5):396-400. DOI:10.1038/nrg1328; Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA. The Potential of MicroRNAs as Prostate Cancer Biomarkers. Eur Urol. 2016;70(2):312-22. DOI:10.1016/j.eururo.2015.12.054; Greco F, Inferrera A, La Rocca R, Navarra M, Casciaro M, Grosso G, Gangemi S, Ficarra V, Mirone V. The Potential Role of MicroRNAs as Biomarkers in Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol Focus. 2019;5(3):497-507. DOI:10.1016/j.euf.2018.01.008; Sharova E, Grassi A, Marcer A, Ruggero K, Pinto F, Bassi P, Zanovello P, Zattoni F, D'Agostino DM, Iafrate M, Ciminale V. A circulating miRNA assay as a first-line test for prostate cancer screening. Br J Cancer. 2016;114(12):1362-6. DOI:10.1038/bjc.2016.151; Paziewska A, Mikula M, Dabrowska M, Kulecka M, Goryca K, Antoniewicz A, Dobruch J, Borowka A, Rutkowski P, Ostrowski J. Candidate diagnostic miRNAs that can detect cancer in prostate biopsy. Prostate. 2018;78(3):178-185. DOI:10.1002/pros.23427; Al-Kafaji G, Said HM, Alam MA, Al Naieb ZT. Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification. Oncol Lett. 2018;16(1):1357-1365. DOI:10.3892/ol.2018.8778; Cochetti G, Poli G, Guelfi G, Boni A, Egidi MG, Mearini E. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role. Onco Targets Ther. 2016;9:7545-7553. DOI:10.2147/OTT.S119027; Dülgeroğlu Y, Eroğlu O. Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases. Microrna. 2020;9(4):303-309. DOI:10.2174/2211536609666201106090458; Knyazev EN, Fomicheva KA, Mikhailenko DS, Nyushko KM, Samatov TR, Alekseev BY, Shkurnikov MY. Plasma Levels of hsa-miR-619-5p and hsa-miR-1184 Differ in Prostatic Benign Hyperplasia and Cancer. Bull Exp Biol Med. 2016;161(1):108-11. DOI:10.1007/s10517-016-3357-7; Jin W, Fei X, Wang X, Chen F, Song Y. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia. J Immunol Res. 2020;2020:5873056. DOI:10.1155/2020/5873056; Wang H, Yang L, Mi Y, Wang Y, Ma C, Zhao J, Liu P, Gao Y, Li P. Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics. Contrast Media Mol Imaging. 2022;2022:6094409. DOI:10.1155/2022/6094409; Coradduzza D, Solinas T, Balzano F, Culeddu N, Rossi N, Cruciani S, Azara E, Maioli M, Zinellu A, De Miglio MR, Madonia M, Falchi M, Carru C. miRNAs as Molecular Biomarkers for Prostate Cancer. J Mol Diagn. 2022;24(11):1171-1180. DOI:10.1016/j.jmoldx.2022.05.005; Abramovic I, Vrhovec B, Skara L, Vrtaric A, Nikolac Gabaj N, Kulis T, Stimac G, Ljiljak D, Ruzic B, Kastelan Z, Kruslin B, Bulic-Jakus F, Ulamec M, Katusic-Bojanac A, Sincic N. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia. Cancers (Basel). 2021;13(9):2068. DOI:10.3390/cancers13092068; Yun SJ, Jeong P, Kang HW, Kim YH, Kim EA, Yan C, Choi YK, Kim D, Kim JM, Kim SK, Kim SY, Kim ST, Kim WT, Lee OJ, Koh GY, Moon SK, Kim IY, Kim J, Choi YH, Kim WJ. Urinary MicroRNAs of Prostate Cancer: Virus-Encoded hsv1-miRH18 and hsv2-miR-H9-5p Could Be Valuable Diagnostic Markers. Int Neurourol J. 2015;19(2):74-84. DOI:10.5213/inj.2015.19.2.74; Kang HW, Byun YJ, Moon SM, Kim K, Piao XM, Zheng CM, Moon SK, Choi YH, Kim WT, Kim YJ, Lee SC, Yun SJ, Kim WJ. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. Investig Clin Urol. 2022;63(2):238-244. DOI:10.4111/icu.20210493; Byun YJ, Piao XM, Jeong P, Kang HW, Seo SP, Moon SK, Lee JY, Choi YH, Lee HY, Kim WT, Lee SC, Cha EJ, Yun SJ, Kim WJ. Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer. Investig Clin Urol. 2021;62(3):340-348. DOI:10.4111/icu.20200488; Guzel E, Karatas OF, Semercioz A, Ekici S, Aykan S, Yentur S, Creighton CJ, Ittmann M, Ozen M. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. Int J Cancer. 2015;136(4):875-9. DOI:10.1002/ijc.29054; Bernardes JGB, Fernandes MR, Rodrigues JCG, Vinagre LWMS, Pastana LF, Dobbin EAF, Medeiros JAG, Dias Junior LB, Bernardes GM, Bernardes IMM, Santos NPCD, Demachki S, Burbano RMR. Association of Androgenic Regulation and MicroRNAs in Acinar Adenocarcinoma of Prostate. Genes (Basel). 2022;13(4):622. DOI:10.3390/genes13040622; Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60(4):809-25. DOI:10.1016/j.eururo.2011.06.037; Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2015;115(4):508-19. DOI:10.1111/bju.12745; Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42(8):1273-81. DOI:10.1016/j.biocel.2009.12.014; Kim WT, Kim WJ. MicroRNAs in prostate cancer. Prostate Int. 2013;1(1):3-9. DOI:10.12954/PI.12011; Плевако Д.С., Князева М.С., Сидина Е.И., Беркут М.В., Рева С.А., Толмачев С.С., Артемьева А.С., Носов А.К., Малек А.В. Влияние таксанов на экспрессию miR-106 и miR-200с клетками рака предстательной железы in vivo и in vitro. Вестник урологии. 2022;10(4):98-108. DOI:10.21886/2308-6424-2022-10-4-98-108; Старцев В.Ю., Шпоть Е.В., Караев Д.К., Кривоносов Д.И. Выявление рака предстательной железы у мужчин молодого и среднего возрастов. Вестник урологии. 2022;10(1):110-120. DOI:10.21886/2308-6424-2022-10-1-110-120; Song C, Chen H, Wang T, Zhang W, Ru G, Lang J. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing. Prostate. 2015;75(5):500-16. DOI:10.1002/pros.22936; Fang YX, Gao WQ. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene. 2014;33(2):135-47. DOI:10.1038/onc.2013.54; Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, Visakorpi T, Egevad L, Lindberg J, Grönberg H, Høyer S, Borre M, Ørntoft TF, Sørensen KD. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res. 2014;20(8):2169-81. DOI:10.1158/1078-0432.CCR-13-2642; Alcaraz A, Hammerer P, Tubaro A, Schröder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009;55(4):864-73. DOI:10.1016/j.eururo.2008.11.011; https://www.urovest.ru/jour/article/view/760
-
20Academic Journal
Authors: Zh. R. Cherkasova, S. A. Tsurkan, A. I. Prostyakova, A. M. Boroda, A. A. Rozhkov, Yu. N. Pirogova, N. M. Nikitina, M. I. Sekacheva, Ж. Р. Черкасова, С. А. Цуркан, А. И. Простякова, А. М. Борода, А. А. Рожков, Ю. Н. Пирогова, Н. М. Никитина, М. И. Секачева
Contributors: The study was conducted with funding of the Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World‑Class Research Centers «Digital bio design and personalized healthcare» № 075‑15‑2022‑304., Работа выполнена при финансовой поддержке Министерства науки и высшего образования Российской Федерации в рамках государственной поддержки создания и развития научных центров мирового уровня «Цифровой биодизайн и персонализированное здравоохранение» № 075–15–2022–304.
Source: Research and Practical Medicine Journal; Том 10, № 1 (2023); 10-26 ; Research'n Practical Medicine Journal; Том 10, № 1 (2023); 10-26 ; 2410-1893 ; 10.17709/2410-1893-2023-10-1
Subject Terms: биопсия предстательной железы, prostate cancer, benign prostatic hyperplasia, prostate‑specific antigen, CA‑62 cancer antigen, prostate biopsy, рак предстательной железы, доброкачественная гиперплазия предстательной железы, простат‑специфический антиген, раковый антиген СА‑62
File Description: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/874/534; International Agency for Research on Cancer. GLOBOCAN 2020: Cancer incidence and mortality worldwide in 2020. Available at: https://gco.iarc.fr/today/fact-sheets-cancers. Accessed: 10.02.2023.; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность).Под ред. Каприна А.Д., Старинского В. В., Шахзадовой А. О. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. Доступно по: https://glavonco.ru/cancer_register/Забол_2020_Электр.pdf. Дата обращения 10.02.2023.; Каприн А. Д. Алексеев Б. Я., Матвеев В. Б., Пушкарь Д. Ю., Говоров А. В., Горбань Н. А., и др. Рак предстательной железы. Клинические рекомендации. Современная онкология. 2021;23(2):211–247. https://doi.org/10.26442/18151434.2021.2.200959; Руководство по ранней диагностике рака. Всемирная организация здравоохранения, 2018, ISBN 978‑92‑4‑451194‑7. Доступно по: https://apps.who.int/iris/bitstream/handle/10665/272264/9789244511947-rus.pdf. Дата обращения 10.02.2023.; Lundgren PO, Kjellman A, Norming U, Gustafsson O. Long‑Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study. J Urol. 2018 Jul;200(1):82–88. https://doi.org/10.1016/j.juro.2018.01.080; Misra‑Hebert AD, Hu B, Klein EA, Stephenson A, Taksler GB, Kattan MW, Rothberg MB. Prostate cancer screening practices in a large, integrated health system: 2007‑2014. BJU Int. 2017 Aug;120(2):257–264. https://doi.org/10.1111/bju.13793; Vickers AJ. Prostate Cancer Screening: Time to Question How to Optimize the Ratio of Benefits and Harms. Ann Intern Med. 2017 Oct 3;167(7):509–510. https://doi.org/10.7326/m17‑2012; Jahn JL, Giovannucci EL, Stampfer MJ. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate‑specific Antigen‑era. Int J Cancer. 2015 Dec 15;137(12):2795–2802. https://doi.org/10.1002/ijc.29408; Сергеева Н. С., Скачкова Т. Е., Маршутина Н. В., Алексеев Б. Я., Каприн А. Д. Клиническая значимость ПСА‑ассоциированных тестов в диагностике и стадировании рака предстательной железы. Онкология. Журнал им. П.А. Герцена. 2018;7(1):55–67. https://doi.org/10.17116/onkolog20187155‑67; Verbeek JFM, Bangma CH, Kweldam CF, van der Kwast TH, Kümmerlin IP, van Leenders GJLH, Roobol MJ. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Urol Oncol. 2019 Feb;37(2):138–144. https://doi.org/10.1016/j.urolonc.2018.11.021; Detsky JS, Ghiam AF, Mamedov A, Commisso K, Commisso A, Zhang L, et al. Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer. J Urol. 2020 Nov;204(5):934–940. https://doi.org/10.1097/ju.0000000000001091; Collins GN, Lloyd SN, Hehir M, McKelvie GB. Multiple transrectal ultrasound‑guided prostatic biopsies‑‑true morbidity and patient acceptance. Br J Urol. 1993 Apr;71(4):460–463. https://doi.org/10.1111/j.1464‑410x.1993.tb15993.x; Демин А. А., Говоров А. В., Васильев А. О. и др. Современный взгляд на биопсию предстательной железы. Consilium Medicum. 2018;20(7):11–14. https://doi.org/10.26442/2075‑1753_2018.7.11‑14; Tcherkassova J, Prostyakova A, Tsurkan S, Ragoulin V, Boroda A, Sekacheva M. Diagnostic efficacy of the new prospective biomarker’s combination CA 15‑3 and CA‑62 for early‑stage breast cancer detection: Results of the blind prospective‑retrospective clinical study. Cancer Biomark. 2022;35(1):57–69. https://doi.org/10.3233/cbm‑210533; Cherkasova JR, Tsurkan SA, Kondratiev VB, Moro‑Vidal R. Cancer antigen for early cancer detection. Patent RU2020114411A, WO2021215955A1 (2021). Available at: https://patents.google.com/patent/WO2021215955A1/en?oq=WO2021215955A1; Патент РФ RU2735918C2 Набор реагентов для выявления маркера эпителиальных карцином.2018.; Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.; Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement. 1960;20:37–46.; Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. 3rd ed. New York: Wiley; 2003.; Gilchrist JM. Weighted 2 x 2 kappa coefficients: recommended indices of diagnostic accuracy for evidence‑based practice. J Clin Epidemiol. 2009 Oct;62(10):1045–1053. https://doi.org/10.1016/j.jclinepi.2008.11.012; Thomsen FB, Westerberg M, Garmo H, Robinson D, Holmberg L, Ulmert HD, Stattin P. Prediction of metastatic prostate cancer by prostate‑specific antigen in combination with T stage and Gleason Grade: Nationwide, population‑based register study. PLoS One. 2020 Jan 29;15(1):e0228447. https://doi.org/10.1371/journal.pone.0228447; Roddam AW, Rimmer J, Nickerson C, Ward AM; NHS Prostate Cancer Risk Management Programme. Prostate‑specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem. 2006 Jan;43(Pt 1):35–48. https://doi.org/10.1258/000456306775141731; Scott RJ, Mehta A, Macedo GS, Borisov PS, Kanesvaran R, El Metnawy W. Genetic testing for homologous recombination repair (HRR) in metastatic castration‑resistant prostate cancer (mCRPC): challenges and solutions. Oncotarget. 2021 Aug 3;12(16):1600–1614. https://doi.org/10.18632/oncotarget.28015; Мусаелян А. А., Назаров В. Д., Лапин С. В., Борискин А. Г., Рева С. А., Лебедев Д. Г., и др. Диагностическая значимость PCA3, TMPRSS2:ERG и производных простатического специфического антигена в выявлении рака предстательной железы. Онкоурология. 2020;16(2):65–73. https://doi.org/10.17650/1726‑9776‑2020‑16‑2‑65‑73; Balk SP, Ko YJ, Bubley GJ. Biology of prostate‑specific antigen. J Clin Oncol. 2003 Jan 15;21(2):383–391. https://doi.org/10.1200/jco.2003.02.083; Kimura T, Sato S, Takahashi H, Egawa S. Global Trends of Latent Prostate Cancer in Autopsy Studies. Cancers (Basel). 2021 Jan 19;13(2):359. https://doi.org/10.3390/cancers13020359; Ha H, Chung JW, Ha YS, Choi SH, Lee JN, Kim BS, et al. Clinical significance of the De Ritis ratio for detecting prostate cancer in a repeat prostate biopsy. Investig Clin Urol. 2019 Nov;60(6):447–453. https://doi.org/10.4111/icu.2019.60.6.447; Говоров А. В., Васильев А. О., Ширяев А. А., Бродецкий Б. М., Садченко А. В., Ковылина М. В., и др. Сравнительный анализ результатов биопсии предстательной железы под контролем ТРУЗИ, системы HistoscanningTM и МРТ: выбор оптимальной тактики для выявления рака предстательной железы. Материалы 12‑го международного конгресса Российского общества онкоурологов. М., 2017, с. 20–21. Доступно по: https://www.calameo.com/books/0045207367ad73a665cd2. Дата обращения: 10.02.2023.; Detsky J, Ghiam AF, Mamedov A, Commisso K, Commisso A, Klotz L, et al. Impact of compliance on outcomes for patients on active surveillance for prostate cancer. Journal of Clinical Oncology. 2019;37(7):36–36. DOI:10.1200/JCO.2019.37.7_suppl.36; Аполихин О. И., Сивков А. В., Шишкин С. В., Шейман И. М., Сон И. М., Катибов М. И., и др. Медико‑экономические аспекты комплексной этапной стандартизованной программы диагностики и лечения доброкачественной гиперплазии предстательной железы. Экспериментальная и клиническая урология. 2014;3:4–8.; https://www.rpmj.ru/rpmj/article/view/874